



# HHS Public Access

Author manuscript

*J Leukoc Biol.* Author manuscript; available in PMC 2020 July 01.

Published in final edited form as:

*J Leukoc Biol.* 2019 July ; 106(1): 147–160. doi:10.1002/JLB.3MIR1218-483RR.

## Below the surface: the inner lives of TLR4 and TLR9

Laura Marongiu<sup>\*</sup>, Laura Gornati<sup>\*</sup>, Irene Artuso<sup>\*</sup>, Ivan Zanoni<sup>\*,†</sup>, Francesca Granucci<sup>\*</sup>

<sup>\*</sup> Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy

<sup>†</sup> Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115, USA

### Abstract

Toll-like receptors (TLRs) are a class of pattern recognition receptors (PRRs) that detect invading microbes by recognizing pathogen-associated molecular patterns (PAMPs). Upon PAMP engagement, TLRs activate a signaling cascade that leads to the production of inflammatory mediators.

The localization of TLRs, either on the plasma membrane or in the endolysosomal compartment, has been considered to be a fundamental aspect to determine to which ligands the receptors bind, and which transduction pathways are induced. However, new observations have challenged this view by identifying complex trafficking events that occur upon TLR-ligand binding. These findings have highlighted the central role that endocytosis and receptor trafficking play in the regulation of the innate immune response.

Here, we review the TLR4 and TLR9 transduction pathways and the importance of their different sub-cellular localization during the inflammatory response. Finally, we discuss the implications of TLR9 subcellular localization in autoimmunity.

### Summary sentence:

review on the importance of TLR4 and TLR9 dynamic subcellular localization in the inflammatory responses.

### Graphical abstract

---


Corresponding author: Laura Marongiu, Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2 20126 Milan, Italy phone +390264483510, [laura.marongiu@unimib.it](mailto:laura.marongiu@unimib.it).

#### Authorship

LM wrote the introduction and the chapters on TLR4 and TLR9 cleavage, corrected the manuscript and drew Figure 1. LG wrote the TLR9 chapter and drew Figure 2. IA wrote the section on intracellular TLRs. IZ revised the review and made suggestions. FG supervised the drafting of the manuscript and performed the final editing.

#### Conflict of interest

The authors declare no conflicts of interest.



TLR4 and TLR9 dynamic subcellular localization.

## Introduction

The innate immune system uses pattern-recognition receptors (PRRs) to sense the presence of invading microbes. PRRs recognize endogenous and exogenous ligands, including pathogen-associated molecular patterns (PAMPs), which are conserved chemical motifs expressed by microorganisms. According to the model proposed by Janeway, the recognition of PAMPs by PRRs is the primary strategy for self- versus non-self-discrimination [1]. Antigen-presenting cells express high levels of PRRs that, upon ligand binding, transduce an intracellular signal, leading to the production of several factors involved in the initiation of the immune response. Ultimately, these events induce the activation of adaptive immunity and the formation of memory cells [2].

Dysregulation of PRR-mediated responses may compromise immunological self-tolerance. For example, aberrant activation triggered by host-derived nucleic acids causes autoimmune disorders, such as Sjögren's syndrome (SS) [3], systemic lupus erythematosus (SLE) [4], multiple sclerosis (MS) [5], systemic sclerosis (SSc) [6], rheumatoid arthritis (RA) [7], and psoriasis [8].

PRRs are classified into five families: Toll-like receptors (TLRs), C-type lectin receptors (CTLs), NOD-like receptors (NLRs), retinoic acid-inducible gene (RIG)-I-like receptors (RLRs), and AIM2-like receptors (ALRs). TLRs are the best-characterized PRRs and are essential modulators of the innate immune response, as they survey both the intracellular and extracellular space [9]. The widespread cellular localization of TLRs confirms their central role in recognizing potential threats and, indeed, some receptors are able to initiate signaling cascades from either the plasma membrane or endosomes.

Here, we provide an overview of the transduction pathways triggered by intracellular TLRs, with a particular focus on the signaling cascades elicited by TLR9 and the intracellular pathways of TLR4. We also discuss how TLR9 signaling may be involved in autoimmunity.

### Intracellular TLRs

TLRs are glycoproteins that consist of three domains: a transmembrane domain, an amino-terminal ectodomain, and a cytoplasmic carboxy-terminal Toll interleukin-1 receptor (IL1-IR) homology (TIR) domain [10, 11]. To activate downstream signaling pathways, TLRs recruit a variety of adaptor proteins, including the TIR-containing adaptor protein (TIRAP), myeloid differentiation primary response 88 (MyD88), the TIR domain-containing adaptor inducing IFN- $\beta$  (TRIF), and the TRIF-related adaptor molecule (TRAM) [12]. Intracellular TLRs (TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13) are expressed in the endoplasmic reticulum (ER), endosomes, multivesicular bodies, and lysosomes; their localization to endosomes and lysosomes, where self-DNA is rarely present, is important to prevent autoimmunity and inappropriate immune responses. Intracellular TLRs recognize either nucleic acids (TLR3, TLR7, TLR8, TLR9 and TLR13) or microbial components (TLR11-TLR12), both derived from the hydrolytic degradation of microorganisms in the endolysosomal compartment [13].

The ligand of TLR3 is double-stranded RNA, such as that of herpes simplex virus 1, which causes encephalitis [14], small interfering RNAs [15], and self RNAs from damaged cells (for example, RNA damaged by ultraviolet B irradiation) [16]. Similarly, TLR7 in plasmacytoid dendritic cells (pDCs) recognizes viral single-stranded RNA, whereas it binds to the RNA of streptococcus B bacteria in conventional dendritic cells (cDCs) [17]. In addition, human TLR8 recognizes viral and bacterial RNA and is preferentially activated by ssRNA rich in AU [18, 19]. On the other hand, TLR9 primarily binds unmethylated CpG DNA motifs, which are common in bacterial and viral DNA; it can also recognize hemozoin, an iron-porphyrin-proteinoid complex derived from the degradation of hemoglobin by malaria parasites [20]. Parroche *et al.*, however, proposed that hemozoin is itself immunologically inert and that its inflammatory activity is due to the presence of parasite DNA in the hemozoin crystal [21]. Another nucleic acid-sensing TLR, TLR13, senses bacterial 23S rRNA [22] and vesicular stomatitis virus [23].

Among the TLRs that recognize microbial components, TLR11 binds to an unknown proteinaceous component of uropathogenic *Escherichia coli* (UPEC) [24] and a profilin-like molecule derived from *Toxoplasma gondii* [25]. TLR12 shares many similarities with TLR11: they both recognize *Toxoplasma gondii*, can form homo- and heterodimers, and can cooperate to recognize their ligands in cDCs and macrophages [26].

Upon ligand binding, intracellular TLRs initiate various signaling pathways. TLR3 induces the expression of inflammatory cytokines and type I interferons by activating TRIF-dependent signaling through a high-affinity interaction between its TIR domain and the TRIF domain. Notably, this binding is completely TRAM-independent [27]. On the other hand, TLR7 and TLR9 activate the transcription factor IRF7 through the MyD88-dependent signaling pathway [28, 29]. TLR3, 7, and 9 become active and trigger downstream signaling following internalization of their ectodomains into endosomes, where they undergo

proteolytic cleavage. This process requires endosomal proteases and is an additional regulatory mechanism that avoids recognition of self-molecules by strengthening the compartmentalization of intracellular TLRs.

The trafficking of intracellular TLRs from the ER to endolysosomes must be strictly controlled to ensure correct signaling cascades. Indeed, intracellular TLRs require the multimembrane protein unc-93 homolog B1 (UNC93B1) to exit the ER and enter the secretory pathway [30]. UNC93B1 controls the packaging of TLRs into coat protein complex II (COPII) vesicles, which then shuttle the TLRs from the ER to the Golgi [31]. The role that UNC93B1 plays in the trafficking of TLRs is different for each receptor [32]. Several chaperone proteins, such as glycoprotein 96 and the protein associated with TLR4 A (PRAT4A), also interact with TLRs and are important for shuttling from the ER [33, 34]. Notably, nucleic acids may enter the cell through different types of endosomes and the specific site of signaling defines the final outcome of the pathway.

## TLR4

Among all PRRs, Toll-like receptor 4 (TLR4) is the best characterized, as it was the first to be discovered in mammalian innate immune cells [35]. Despite TLR4 mainly residing in the plasma membrane, it can also be considered as an intracellular TLR, because it can be internalized and stimulate intracellular pathways [36]. Moreover, although still controversial, it has been proposed that TLR2 also activates NF- $\kappa$ B from endosomes in human monocytes [37] and induces the production of type I interferon in mouse Ly6C<sup>high</sup> inflammatory monocytes in response to viral ligands [38]. Thus, the endocytic machinery assumes a pivotal role in the regulation of pathways elicited by TLR4 and perhaps TLR2.

The main ligand of TLR4 is lipopolysaccharide (LPS), the major component of the outer membrane of Gram-negative bacteria. LPS is composed of lipids and carbohydrates, with a high level of structural complexity, and consists of three different components: i) the O antigen, an O- polysaccharide chain of variable length; ii) the core oligosaccharide; and iii) lipid A, which contributes to most of the immunostimulatory activity of the molecule [39]. The O antigen is specific for each bacterial strain and affects colony morphology; microbial variants with full-length O-polysaccharide chains form smooth colonies, whereas those lacking or carrying reduced chains form rough colonies [40].

Despite TLR4 being the central mediator of innate and adaptive immune responses induced by LPS, endotoxin recognition also requires other surface molecules. Indeed, TLR4 forms the LPS multi-receptor complex with LPS binding protein (LPB), glycosylphosphatidylinositol (GPI)-anchored protein CD14, and myeloid differentiation 2 (MD-2) [12]. LPB is a soluble protein that binds large LPS aggregates on the bacterial cell wall [41], leading to LPS disaggregation and the presentation of monomers to CD14 [42]. Upon LPS stimulation, CD14 promotes re-localization of the TLR4-MD-2 complex to lipid rafts, which are enriched in PIP2 (phosphatidylinositol 4,5-bisphosphate) [43, 44]. At this point, TLR4 dimerizes and can initiate signal transduction from both the plasma membrane and the endosome; on the plasma membrane, PIP2 binds to TIRAP and mediates the activation of the Myd88 pathway [45] (Figure 1A), whereas TLR4 activates the TRAM-TRIF pathway upon internalization into the endosome (Figure 1B) [36]. The coordinated

actions of all the proteins of the LPS multi-receptor complex, combined with the ability of CD14 and MD-2 to sense and bind LPS, even at picomolar concentrations, ensures the detection of bacteria with high sensitivity [46].

Recent data have shown that not only TLR4 but also CD14 can sense LPS. Indeed, the surface molecule CD14 alone is able to activate a signaling cascade in response to LPS, leading to activation of the nuclear factor of activated T-cells (NFAT) in DCs (Figure 1A) [47]. Moreover, several studies have demonstrated that intracellular LPS activates the formation of a caspase-11-dependent noncanonical inflammasome [48–50]. More recently, Shi *et al.* have identified the receptors for intracellular LPS by showing that caspase-11 in mice and caspase-4 and –5 in humans directly bind LPS. [51].

### TLR4 plasma membrane and endosomal signaling

TLR4 activates two signaling pathways. From the plasma membrane, the receptor induces the TIRAP-MyD88 pathway, which activates NF- $\kappa$ B and AP-1. From the endosome, TLR4 initiates the TRAM-TRIF pathway, leading to the activation of IRF3, the production of type I IFNs (type I interferons), and a late wave of NF- $\kappa$ B activation [36].

As recently reviewed by Brubaker et al. [12], upon TLR4 activation, TIRAP facilitates the interaction of MyD88 with TLR4 via its TIR domain, leading to the formation of the so-called ‘myddosome’, a large molecular platform composed of MyD88, TIRAP, and IRAK proteins [52, 53]. IRAK4 activates both IRAK1 and IRAK2, which, in turn, recruit TRAF6. TRAF6 interacts with TAB1, TAB2, TAB3, and TAK1, regulating the activation of NF- $\kappa$ B and AP-1 via IKKs and MAPK, respectively (Figure 1A) [12].

After the first wave of NF- $\kappa$ B and AP-1 activation, the bipartite sorting signal of the adaptor protein TRAM controls trafficking of the entire LPS receptor complex to the endosomal compartment [36]. During internalization, the TIRAP-MyD88 complex is released from the invaginating plasma membrane, allowing TRAM-TRIF to engage the TIR domain of TLR4 [36]. The first step for TRIF-dependent IRF3 activation entails the recruitment of TRAF3 to TRIF. In turn, TRAF3, by interacting with TANK, recruits TBK1 and IKK $\epsilon$ ; this complex then activates IRF3 and induces the production of Type I IFNs (Figure 1B) [54, 55]. It has become clear over the last 10 years that both plasma-membrane and endosome signaling of TLR4 are required for the full response to LPS, highlighting the importance of both the internalization process and the molecules involved. In addition to the two main signaling pathways of TLR4, TLR4 intracellular signaling boosts micropinocytosis and antigen presentation [56, 57] and, recently, it has also been shown to be involved in the recognition and uptake of apoptotic cells [58].

### Endocytosis of TLR4

After the first wave of NF- $\kappa$ B activation, the LPS receptor complex is internalized and redirected to the endosome. A series of studies have underlined the central role of CD14 in this process and have demonstrated that the production of type I IFN depends on CD14, highlighting the essential role of CD14 in the induction of the type I IFN-mediated response against Gram-negative bacteria. In particular, it has been shown that the TLR4-CD14-TRAM-TRIF pathway is required for the induction of IFN- $\gamma$  production in NK cells during

Gram-negative bacterial infections [59]. Jiang *et al.* demonstrated that CD14 is absolutely required for both activation of the TRAM-TRIF pathway and the production of type I IFN in response to smooth and rough LPS, despite its being dispensable for the detection of high doses of LPS by the complex [60].

Two studies have described how CD14 orchestrates endosomal re-localization of the LPS complex: CD14-dependent TLR4 endocytosis, called 'inflammatory endocytosis', is mediated by the activation of the tyrosine kinase Syk and phospholipase C $\gamma$ 2, of which the activation is regulated by ITAM and the adaptors DAP12 and Fc $\epsilon$ R $\gamma$  (Figure 1B) [56, 61].

A recent study has proposed that the channel TRPM7 (transient receptor potential cation channel, subfamily M, member 7) is involved in LPS-induced TLR4 endocytosis in macrophages by mediating calcium influx (Figure 1B) [59]. Indeed, the authors showed that both genetic deletion of *trpm7* and pharmacological inhibition of the channel abolish, at least partially, the calcium influx in response to LPS, preventing TLR4 internalization [62]. However, TRPM7 may control the recycling of TLR4 rather than its internalization [63]. Further research is needed to clarify the mechanism by which TRPM7 regulates TLR4 endocytosis.

Recently, a study has clarified how TLR4 is selected as cargo for endocytosis [64]. Starting from the observation that the endocytosis of CD14 occurs constitutively in resting cells, the authors hypothesized that the tail of TLR4 is dispensable for the initiation of TLR4 internalization. As a TLR4 mutant lacking intracellular domain did not abrogate the process, the authors inferred that the cargo-selection agent resided in the extracellular portion and hypothesized the involvement of the interaction between TLR4 and MD-2. Indeed, they discovered that both direct binding of MD-2 to the TLR4 ectodomain and MD-2-dependent TLR4 dimerization promote TLR4 endocytosis [61]. Thus, MD-2 plays a key role in TLR4 signaling by coordinating both signal transduction and endocytosis.

Depending on the cell type, the endocytosis of TLR4 involves different players. For example, a specific role for CD11b in promoting the endocytosis of TLR4 has been found in DCs but not in macrophages, as the absence of the integrin affects the process only in DCs [65]. Notably, CD11b is required for the correct internalization of TLR4 only in cells with low levels of CD14 [69]. Indeed, the treatment of CD11b-deficient DCs with CpG DNA leads to higher levels of expression of CD14 that compensate the TLR4 internalization defect of the cells. However, CpG treatment does not rectify the defect that the cells have in the TRIF/IRF3 pathway, showing that CD11b plays another role in addition to the modulation of TLR4 trafficking [65].

The endocytosis of TLR4 is negatively regulated by the metalloproteinase CD13. CD13 is upregulated in the presence of LPS and inhibits TRIF signaling in DCs, as shown by higher levels of TLR internalization in CD13-deficient cells [66]. How CD13 negatively regulates TLR4 trafficking is not yet clear, but neither the inhibition of MD-2 nor the inhibition of CD14 seem to be involved [66].

Perkins *et al.* described a new negative-feedback loop driven by the PGE2-EP4 axis that specifically inhibits TLR4-mediated TRIF-dependent type I IFN production by regulating



TLR4 trafficking. Specifically, PGE2 is rapidly secreted and acts in an autocrine-paracrine regulatory loop in response to bacterial LPS [67].

Finally, it is worth noting that pathogenic and commensal bacteria prevent TLR4 endocytosis by producing dephosphorylated LPS to evade detection and CD14-mediated transport to the endosome [64].

### **It's all about trafficking: the path of TLR9 into the endolysosomal system**

The complexity of the endosomal system fine-tunes the immune response by ensuring the correct compartmentalization of intracellular TLRs and their ligands.

In resting cells, TLR9 is localized to the ER [30, 68, 69] and requires endosomal shuttling to initiate signal transduction. TLR9 engagement can culminate in two outcomes: the activation of IRF in the IRF-signaling endosomes (IRF-SE) and the activation of NF- $\kappa$ B in the NF- $\kappa$ B-signaling endosomes (NF- $\kappa$ B-SE). Thus, the TLR9 signaling pathway has been defined as “bifurcated” [70]. Specifically, the trafficking of TLR9 and its ligand to the IRF-SE leads to the production of type I IFN, whereas localization to the NF- $\kappa$ B-SE induces the expression of pro-inflammatory cytokines, via IRF and NF- $\kappa$ B respectively.

Several checkpoints control TLR9 shuttling through vesicles and involve several membrane and adaptor proteins [70], actin-nucleation factors, cytoskeletal remodeling proteins [71], lysosome- or vesicle-associated membrane proteins (LAMPs and VAMPs) [72], and folding chaperones. For example, UNC93B1 facilitates TLR9 trafficking from the ER to the Golgi [32] and then controls the loading of TLR9 into COP II<sup>+</sup> vesicles, which deliver the receptor to the plasma membrane [31]. At the cell membrane, UNC93B1 recruits the adaptor protein AP-2 via its C-terminal Yxx $\Phi$  motif and mediates clathrin-dependent internalization of TLR9, leading to localization of the receptor to early endosomal compartments [68, 69]. The early endosomes that contain TLR9 and its ligand are still poorly characterized.

The Brain and DC-associated LAMP-like molecule (BAD-LAMP) is a member of the lysosome-associated membrane glycoproteins and controls, together with UNC93B1, the trafficking of TLR9 [72]. It is expressed by pDCs, which produce the largest amount of type I IFNs in response to viral infections [73, 74]. Indeed, in human pDCs, BAD-LAMP co-localizes with UNC93B1 from the ER to an endosomal hybrid compartment, the IRF-SE, which expresses both VAMP3 and LAMP2. From the IRF-SE, BAD-LAMP directs and promotes the trafficking of TLR9 to a LAMP1<sup>+</sup> late endosome, the NF- $\kappa$ B-SE, leading to the production of pro-inflammatory cytokines [72].

In murine bone marrow-derived DCs (BMDCs), the intermediate VAMP3<sup>+</sup> endosome contains insulin-responsive aminopeptidase (IRAP), a type II transmembrane protein. IRAP is involved in antigen processing for cross-presentation via MHC I [75–77], but recently a new role in TLR9 trafficking has been proposed, as TLR9 and its ligand are cargo of IRAP<sup>+</sup> intermediate endosomes [71]. In IRAP<sup>+</sup> endosomes, IRAP interacts with forming-homology-domain-containing protein 4 (FHOD4), a protein that promotes actin assembly on endosomes; their interaction delays TLR9 trafficking and limits the shuttling of TLR9 to

LAMP<sup>+</sup> lysosomes by enhancing endosome retention. Accordingly, IRAP-deficient DCs show higher levels of IRF7 and NF- $\kappa$ B activation than wildtype DCs [71].

**The game changer: AP-3**—The signaling cascade triggered by TLR9 depends on intracellular trafficking of the receptor. APs select the cargo in the vesicles and, specifically, AP-3 determines whether TLR9 is addressed to IRF-SE to promote type I IFN production [70]. Indeed, AP-3 is required for the formation of lysosome-related organelles (LROs) [78, 79], in which one of the two TLR9 signaling cascades occurs, depending on the origin of the cell.

Iwasaki *et al.* have proposed that TLR9 from the Golgi enters NF- $\kappa$ B-SEs (characterized by the expression of VAMP3 and PI(3,5)P<sub>2</sub> and the lack of LAMP2 expression), where it promotes the transcription of pro-inflammatory cytokines in murine bone-marrow derived pDCs. In NF- $\kappa$ B-SEs, AP-3 interacts with TLR9 and induces shuttling of the receptor to LAMP2<sup>+</sup> LROs (IRF-SEs), resulting in the production of type I IFN [70].

Consistent with Iwasaki's model, Blasius *et al.* found that AP-3 is essential for the induction of type I INF production, specifically in pDCs [78]. They observed that pDCs derived from mice with mutations in AP-3b1 (*Ap3b1<sup>pearl/pearl</sup>* and *Ap3b1<sup>bullet gray/bullet gray</sup>* [80]) fail to produce both type I IFNs and TNF- $\alpha$  upon TLR9 activation. However, the release of cytokines in cDCs isolated from the same animals was unaffected [78], confirming the intrinsic difference between pDCs and cDCs. In accordance with these results, the pDCs of Hermansky-Pudlack syndrome type 2 patients, with AP-3 defects, exhibit reduced IFN- $\alpha$  production upon challenge with Herpes simplex virus-1 (HSV-1) [81].

Conversely, Combes *et al.* reported that the production of type I IFNs was unaffected by silencing of AP-3 in a human pDC cell line (CAL-1). However, they demonstrated that the AP-3 complex contributes to shifting endosomal compartments by promoting TLR9 and BAD-LAMP access to late endosomes for the activation of the NF- $\kappa$ B pathway [72].

Finally, several studies have suggested that AP-3 is regulated by the phosphoinositide 3-phosphate 5-kinase (PIKfive), a kinase that controls the status of the phosphorylated derivatives of phosphatidylinositol (PI), key components of cell membranes [82]. It has been shown that PIKfive and phosphorylated PIs regulate TLR signaling by orchestrating their intracellular pathways [83, 84]. Specifically, in NF- $\kappa$ B endosomes, PIKfive converts PI(3)P to PI(3,5)P<sub>2</sub> [85], which recruits and interacts with AP-3 [86]. Thus, PIKfive ensures the correct trafficking of TLR9 and CpG to type I IFNs-SE [87] by guaranteeing both the recruitment of AP-3 and the generation of LROs [88]. Moreover, an additional role of PIKfive in pDCs has been suggested, as its inhibition suppresses both IRF7 and NF- $\kappa$ B pathways in pDCs, whereas it abrogates only type I IFN production in cDCs [88]. The role of AP-3 in generating LROs thus appears to be clear, although the signaling cascade that is triggered from the LROs is still a matter of debate.

### It's all about trafficking: CpG is looking for a receptor

The trafficking of TLR9 to endosomal compartments is of utmost importance for the initiation of signaling cascades. However, CpG also requires controlled shuttling to



endolysosomes to encounter TLR9 and activate the pathways. Indeed, upon CpG stimulation of human DCs, the DNA undergoes rapid clathrin-dependent and caveolin-independent internalization into vesicles that localize in juxtannuclear areas [68]. Then, TLR9 is actively shuttled to CpG-rich compartments because of the recruitment of MyD88 in the vesicles. Two studies have also shown that CpG trafficking affects the efficiency of TLR9 signaling, as the abrogation of CpG trafficking to the LAMP<sup>+</sup> late compartment impairs TLR9 pathways [87, 88].

Some of the molecules involved in the shuttling of CpG to the endolysosomal system are discussed below.

**Granulin**—CpG interacts with a co-receptor that delivers it to the endolysosomes: granulin [89, 90]. Granulin coordinates CpG trafficking to TLR9-rich vesicles, where it promotes the interaction between the ligand and the C-terminal domain of TLR9, guaranteeing activation of the signaling cascade [89].

Granulin is a cysteine-rich protein [91] involved in several biological processes, such as wound healing [92], embryonic development, and cell growth [93, 94]. Park *et al.* first identified granulin in RAW macrophages by mass spectrometry, as it was among the polypeptides that co-immunoprecipitated with TLR9 in protease-inhibited RAW macrophages [90]. This study also confirmed the importance of granulin for the activation of TLR9 signaling. The addition of granulin to the macrophage culture increased TNF- $\alpha$  production only upon CpG stimulation, whereas the removal of secreted granulin reduced the amount of TNF- $\alpha$  released by the cells [90]. Moreover, BMDMs and pDCs isolated from granulin-deficient mice exhibit impaired TNF- $\alpha$  and IL-6 production upon CpG treatment.

Several studies have also suggested that granulin plays a role in autoimmunity. Tanaka *et al.* found high levels of granulin in the serum of patients with systemic lupus erythematosus (SLE) [95]; Xiong *et al.* later confirmed the same result in a mouse model of SLE and linked the increased amount of granulin to an aggravation of lupus nephritis, a clinical manifestation of SLE [96, 97]. Therefore, granulin appears to worsen the autoimmune status of both humans and mice. Indeed, Xiong *et al.* demonstrated that granulin promotes the shifting of macrophage polarization toward an M2b phenotype, leading to increased production of pro-inflammatory cytokines, such as TNF- $\alpha$ , IL-6, and IL-1 $\beta$  [96]. As TLR9 pathway activation in macrophages induces M1 polarizing signaling [98], it is likely that granulin-mediated M2b polarization involves an additional receptor or an alternative mechanism. In addition, Chen *et al.* focused on macrophages, excluding pDCs and B cells from the scenario of activated lymphocyte-derived DNA-induced lupus nephritis [96]. Hence, the role of granulin in autoimmunity appears to be poorly characterized, in particular regarding type I IFN production upon TLR9 engagement in pDCs. Overall, these results highlight the unclear role of granulin in both the TLR9 pathway and autoimmune diseases.

**HMGB1**—Another co-factor that facilitates DNA sensing is high-mobility group box 1 (HMGB1). HMGB1 is a multifunctional protein that resides in the nucleus and regulates chromatin structure [99–101], V(D)J recombination [102, 103], and gene transcription [104]. Upon tissue damage, HMGB1 is secreted by necrotic cells [105], whereas immune

cells actively release it during infections and when stimulated by inflammatory mediators [106].

To date, only a few studies have investigated the role of HMGB1 in the immune response. Tian *et al.* showed, that HMGB1 binds to bacterial and mammalian DNA, as well as CpG by treating peripheral blood mononuclear cells (PBMCs) with sera from SLE patients [107]. The authors suggested that HMGB1 may catalyze the TLR9-mediated response to DNA, as it enhances the stimulatory effect of CpG on pDCs by increasing the production of both IFN- $\alpha$  and TNF [107]. In addition, the authors demonstrated that, in pDCs, the HMGB1-DNA complex binds to the receptor for advanced glycation end-products (RAGE), which in turn interacts with TLR9, increasing the production of type I IFN production by pDCs via the internalization of DNA [107]. The crucial role of the HMGB1-RAGE axis in TLR9 regulation has also been confirmed by Tian *et al.*, who treated PBMCs with sera collected from SLE patients and necrotic cell supernatants, showing that DNA complexes in the sera induced type I IFN production. This induction was abrogated by treating necrotic cells with inhibitors of HMGB1 or RAGE [107].

Accordingly, Ivanov *et al.* demonstrated that HMGB1 binds to CpG in BMDCs and BMDMs and plays an essential role in enhancing the release of pro-inflammatory cytokines [108]. The authors showed that the augmented response was not due to increased internalization of HMGB1-CpG, but to a more rapid interaction between TLR9 and CpG. Indeed, HMGB1 already co-localizes with TLR9 in early vesicles in BMDMs prior to CpG stimulation and accelerates TLR9 redistribution to early endosomes in response to CpG-ODN. [108]. As HMGB1 secretion increases when BMDMs and BMDCs are treated with CpG, it is likely that HMGB1 acts at two levels: in the extracellular space by binding to CpG and in the intracellular space by hastening TLR9 shuttling and, thus, catalyzing the TLR9 signaling cascade [107, 108].

### **The controversial role of TLR9 proteolytic cleavage events**

An additional mechanism that limits TLR9 activation involves a multistep proteolytic cleavage that is required for MyD88 recruitment and the triggering of both signaling cascades [109]. The cleavage of TLR9 occurs in endolysosomal compartments as an evolutionary strategy to prevent aberrant self-recognition, such that the 150 kDa full-length receptor on the plasma membrane, which is potentially in contact with self-DNA, remains non-functional.

In the endolysosomes of macrophages, lysosomal cathepsins and endopeptidases, which function only at acidic pH, cleave the TLR9 ectodomain between LRR14 and 15 into an 80 kDa protein [109–111]. Additional proteolytic events that involve asparagine endopeptidase occur in both myeloid and plasmacytoid DCs, showing that different cell types may activate specific proteolytic pathways [112, 113].

Other studies have shown how TLR9 proteolysis fine-tunes downstream signaling, by showing that alternative cleavage of endogenous TLR9 negatively regulates its signal transduction. Specifically, Chockalingam *et al.* described a novel proteolytic cleavage that results in the formation of soluble TLR9 (sTLR9), which binds to CpG DNA and hinders

TLR9 transduction. The authors showed that the neutralization of endosomal pH had no effect on TLR9 formation, suggesting that the alternative cleavage may depend on cathepsin S, a protease active at both acidic and neutral pH [114].

Similarly, another study found an N-terminal cleavage product of TLR9 that negatively regulates its signaling; by binding to the C-terminal fragment, the N-terminal product accelerates the dissociation of C-terminal homodimers and promotes its aspartic protease-mediated degradation. This autoregulatory negative-feedback mechanism may prevent excessive TLR9 signaling [115]. In contrast, Onji *et al.* showed that the N-terminal cleavage product of TLR9 is required for signaling [116]. These discordant results highlight the complex regulation of TLR9 signaling controlled by its own processing and cleavage products.

Finally, Sinha *et al.* showed that the cleaved and mature form of TLR9 (the C-terminal fragment TLR9<sup>471–1032</sup>) is by itself unable to respond to CpG DNA when transfected into TLR9-deficient macrophages or DCs. Moreover, its activity was not rescued either by the co-expression of the N-terminal fragment, which fails to restore the native glycosylation pattern of TLR9<sup>471–1032</sup>, or inclusion of the cleavage site [117]. These data suggest that TLR9<sup>471–1032</sup> is generated from full-length TLR9 in the endosome in the presence of its ligand; if these conditions are not met, the active form is not properly glycosylated and may act as a negative regulator [117].

### Downstream TLR9 engagement

Signal transduction begins once TLR9 and its ligand enter the endolysosomal system. TLR9 engagement leads to the recruitment of different players, depending on the cell type. In cDCs, macrophages, and pDCs, TLR9 activates the signaling cascade that culminates with the production of pro-inflammatory cytokines, such as TNF- $\alpha$ , IL-6, and IL-12. Instead, the receptor initiates the pathway that leads to type I IFN release primarily, but not exclusively, in pDCs. These two signaling cascades are discussed in detail below.

**TIRAP: an adaptor only for the TLRs on the plasma membrane?**—Several studies have investigated whether intracellular TLRs require sorting adaptor molecules, such as TIRAP, to signal. The sorting capacity of TIRAP relies on its amino-terminal localization domain, which was initially believed to strictly localize TIRAP at the plasma membrane, in association with PI(4,5)P2 [84, 118]. However, the group of Jonathan Kagan shed new light on the role of TIRAP in TLR9 signaling [119]. They challenged wildtype and TIRAP-knockout BMDMs and pDCs with either CpG or specific HSV-1 strains that are sensed only by TLR9, as reported by Sato *et al.* [120]. Intriguingly, IL-1 $\beta$  and IL-6 production was impaired only in TIRAP-knockout BMDMs stimulated with HSV-1. Their results suggest that TIRAP plays a crucial role in sensing natural TLR9 ligands, such as HSV-1 [119]. Conversely, Piao *et al.* reported less production of TNF- $\alpha$  and IL-6 after CpG stimulation of primary macrophages treated with 2R9, a peptide that binds TIRAP, inhibiting its binding to TIR domains. Thus, the role of TIRAP in macrophage activation upon TLR9 challenge may depend on the stimulus and may enhance Myddosome formation [121].

Bonham *et al.* also investigated how TIRAP influences the signaling of intracellular TLRs by stimulating wildtype and TIRAP-knockout pDCs. The authors chose pDCs as their *in vitro* model because these cells respond to infections exclusively via endosomal TLRs [119] and allow investigation of the functions of TIRAP in the various endosome populations that generate the bifurcated pathway [70]. Intriguingly, upon HSV stimulation, TIRAP knockout pDCs were unable to produce IFN- $\alpha$  but not IL-12p40 [119]. These results suggest that TIRAP is essential for the signaling that begins from late endosomal compartments [70]. Finally, the authors confirmed that TIRAP can bind to multiple lipids [122] and showed that its interaction with 3' PIs and phosphatidylserine (PS) in the endosome is sufficient to promote the TLR9 signaling that leads to type I IFN production [119]. Recently, Ve *et al.* proposed a sequential and cooperative model for the assembly of TIR-signaling complexes. Their structural and kinetic data demonstrate that sequential monomer addition, rather than dimerization and trimerization, is more favorable, providing a more sensitive response [123]. Javmen *et al.* also investigated the role of TIRAP in TLR9 signaling by screening a peptide library derived from TLR9 TIR. They uncovered inhibitory peptides that block TLR9 signaling *in vitro* and *in vivo*. In particular, they showed that the 9R34- N peptide can bind to both TLR9 TIR and TIRAP TIR, suggesting a common mode of TIR domain interaction in the primary receptor complex [124].

**The production of pro-inflammatory cytokines**—Once the ligand binds to the leucine-rich repeats in the ectodomain of TLR9, the receptor undergoes a conformational change that allows the formation of homodimers and association of the TIR domains [125]. Depending on the cell type and stimulus, the juxtaposed TIR domains recruit TIRAP (Bonham et al., 2014; Piao et al., 2015) and the adaptor molecule MyD88, which interacts with IRAK4 through its N-terminal death domain (DD) [126]. IRAK4 phosphorylates and activates IRAK1 and IRAK2, which then activate the E3 ubiquitin ligase TRAF6 [127, 128]. TRAF6 mediates the formation of K63-linked polyubiquitin chains on NF- $\kappa$ B essential modulator (NEMO or IKK $\gamma$ ) and itself [129]. These chains create a scaffold for the recruitment of TAB2 and allow the formation of a multiprotein complex composed of TRAF6 [130], NEMO, TAB2, TAB1, and TAK1 [131]. In parallel, the NEMO recruits IKK $\beta$ , which is phosphorylated by TAK1 [132, 133]. Activation of the IKK proteins [134] results in the phosphorylation of I $\kappa$ Bs [135], which leads to their degradation and the translocation of NF- $\kappa$ B to the nucleus. At the same time, TAK1 mediates the activation of the MAPK-signaling cascade, resulting in the nuclear translocation of AP-1 [136]. Simultaneously, IRF1 and IRF5 are directly activated by MyD88 [137, 138]. Finally, the activated IRFs, NF- $\kappa$ B, and AP-1 induce the expression of pro-inflammatory cytokines (TNF- $\alpha$ , IL-6, and IL-12).

**The production of Type I IFN**—Several studies have shown that only pDCs produce type I IFN following TLR9 engagement; however, cDCs and macrophages can also release IFNs upon TLR9 challenge [139, 140]. Here, we describe the signaling pathway in pDCs, the major producers of type I IFN.

**pDCs and type I IFN production**—Type I IFN production by pDCs is essential to protect the host against viral infections [141]. Whether the signal from the IRF-SE occurs

sequentially or simultaneously to that triggered from the NF- $\kappa$ B-SE is still under discussion. Once AP-3 interacts with TLR9 and shuttles from the NF- $\kappa$ B-SE to the LROs, the pathway forks [70]. At this point, TIRAP acts as a sorting adaptor and is required for the formation of the myddosome, a multiprotein complex. MyD88 recruits IRAK4 [141, 142], which then interacts with TRAF6, TRAF3 [143, 144], and IRAK 1 [145]. Once this multiprotein complex has formed, IRF7 association with MyD88 and TRAF6 promotes IFN- $\alpha$  production [28, 29, 146]. In addition, IKK $\alpha$  enhances IFN- $\alpha$  release via IRF7 phosphorylation [147]. Hence, IRF7 disassociation from the complex and its translocation to the nucleus induce type I IFN transcription.

An additional player in the pathway is osteopontin (OPN), which contributes to the induction of IFN- $\alpha$  production, specifically in pDCs, because they express intracellular OPN, as opposed to cDCs, which do not. Although the precise mechanism by which OPN supports type I IFN release is still unknown, it is considered to be a functional member of the multiprotein complex. Indeed, upon TLR9 engagement, it localizes near TLR9 and MyD88, favoring the IRF7 pathway [148]. The importance of OPN in TLR9 signaling has also been confirmed by the fact that OPN-deficient animals produce reduced levels of IFN- $\alpha$  when challenged with inactivated HSV [148].

Another pathway that supports type I IFN release is phosphoinositol 3-OH kinase (PI3K)-mTOR signaling. The pharmacological inhibition of the kinase or mTOR reduces the interaction between TLR9 and MyD88 and impairs the production of type I IFN [149]. The mechanism by which PI3K promotes IRF7 activation and translocation into the nucleus in human pDCs has not yet been fully dissected [143], but it is likely that PI3K acts together with other regulatory elements of the pathway.

Finally, type I IFN is a positive regulator of its own pathway; it enhances the expression of TLR9 and MyD88, further increasing its production [72].

### **Autoimmunity: the case of TLR9**

The etiopathogenesis of most autoimmune diseases is still unclear, as several factors may contribute to their onset, such as the presence of autoantibodies, high serum levels of type I IFNs [150], or increased cell death, which trigger diseases such as rheumatoid arthritis (RA) and system lupus erythematosus (SLE) [145]. As the insufficient clearance of necrotic cells in RA and SLE results in the accumulation of nucleic-acid containing material [151], researchers have investigated whether TLR9 is involved in these autoimmune responses. Indeed, in contrast to TLR4, the dysregulation of TLR9 signaling has been associated with autoimmunity, even though its precise role is still a subject of debate. A study has shown that the receptors for the Fc region of IgG (Fc $\gamma$ R) sense immune complexes and induce their entry into the endosomal system, where self-DNA encounters TLR9. This leads to higher production of both pro-inflammatory cytokines and type I IFNs [152]. Accordingly, the activation of the TLR9 pathway in pDCs and autoreactive B cells has been associated with SLE and RA [4, 153, 154]. Below, we provide a brief overview of the findings that have suggested how TLR9 may be involved in specific autoimmune diseases

**Systemic Lupus Erythematosus**—Several lines of evidence support the involvement of TLR9 in the onset of SLE. First, SLE patients exhibit an altered balance in the circulating subtypes of DCs, as their pDC compartment, specialized in the production of type I IFN, is more prominent than normal [155]. Second, B cells and monocytes from SLE patients are characterized by increased levels of TLR9 expression, which correlate with higher levels of autoantibodies against dsDNA [154, 156]. Moreover, aside from the crucial role of TLR7 in the pathogenesis of SLE, it appears that only TLR9 is required for one of the hallmarks of SLE: the production of anti-DNA antibodies [157].

Despite these results, other studies support the hypothesis that TLR9 has a protective role in the pathogenesis of SLE. For example, TLR9-deficient mice exhibit clear lupus-like clinical manifestations [158] and TLR9<sup>-/-</sup> autoimmune-prone MRL/lpr animals have a shorter lifespan due to severe SLE and glomerulonephritis [4]. Consistent with these results, another study has proposed that TLR9 acts as a negative regulator of TLR7, the main culprit of SLE pathogenesis [158], by competing for UNC93B1 in the ER [159, 160]. Indeed, a point mutation in UNC93B1 (D34A) facilitates the association with TLR7 and dampens TLR9 activity, leading to severe systemic inflammation in Unc93b1<sup>D34A/D34A</sup> mice [160].

**Rheumatoid arthritis**—The role of TLR9 in RA is still a subject of debate. On the one hand, some studies have proposed that TLR9 worsens the severity of RA [161]. For example, Asagiri *et al.* showed that the treatment of adjuvant-induced arthritic rats with an inhibitor of cathepsin K led to defective TLR9 signaling and improvement of their pathological state, even though the role of this protease in the TLR9 signaling pathway is still poorly understood [153]. On the other hand, Miles *et al.* reported that the administration of apoptotic cells in a murine model of collagen-induced arthritis led to a TLR9-dependent anti-inflammatory effect, supporting the hypothesis that TLR9 signaling is protective against RA [162].

**Psoriasis**—Another molecule that promotes aberrant activation of TLR9, thus inducing autoimmune diseases, is the anti-microbial cathelicidin LL37, a hallmark of psoriasis also found in synovial membranes of arthritis patients [163]. Human LL37 is a carboxy-terminal peptide fragment derived from the cathelicidin precursor (human cationic antibacterial protein of 18 kDa orhCAP18) and has many anti-microbial properties [164]. Upon tissue damage, LL37 binds covalently to self-DNA in pDCs and facilitates DNA internalization into the endolysosomal system; once in the endosome, TLR9 may bind to self-DNA, inducing type I IFN production and triggering the onset of psoriasis [165, 166]. Also, LL37 in keratinocytes contributes to the exacerbation of psoriasis via the activation of TLR9 and the production of type I IFN [167, 168].

**Intracellular TLRs and other autoimmune diseases**—Aside from the aberrant sensing of self-DNA by TLR9, autoimmune diseases may also result from the misregulation of intracellular TLR9 trafficking. Indeed, it has recently been demonstrated that improper trafficking may be related to autoimmunity via perturbation of intracellular TLR pathways [169]. For example, mice lacking one of the components of the SWC complex (a protein complex involved in autophagy and endocytosis and composed of Smith-Magenis syndrome chromosome region candidate 8 SMCR8, WD repeat domain 41 WDR41, and C9ORF72)



exhibit impaired intracellular TLR signaling that leads to autoimmunity reactions and systemic inflammation [170]. Indeed, SMCR8 negatively regulates endosomal TLR signaling, and the entire complex contributes to the vesicle acidification required to degrade TLR ligands and avoid persistent stimulation [169]. A study has also suggested that amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in humans could be caused by *C9ORF72* repeat expansion because it generates a loss-of-function SWC complex [171]. Thus, the role of TLR9 in distinct autoimmune disorders is still unclear and further insights are required to shed light on the context-dependent effects of the engagement of this receptor.

### Concluding remarks

Over the last few years, a more comprehensive picture of the plasma membrane and intracellular signaling cascades, networks, transcriptional regulation, and other processes associated with the TLR response has emerged. In this review, we have discussed up-to-date knowledge of the regulation of the pathways elicited by TLR4 and TLR9 and their roles in host defense and autoimmunity.

Endocytosis and protein trafficking in TLR4 signaling are recently identified regulatory mechanisms of innate immunity and many studies have focused on the identification of the molecules involved in their modulation, leading to the discovery of new players and functions. For example, CD14 and MD-2 are now considered to comprise a novel category of regulators of innate immunity, called transporter associated with the execution of inflammation (TAXI), rather than “classic” chaperone proteins [172].

The trafficking of TLR9 has also emerged as a crucial checkpoint of its pathway, as adaptor proteins, LAMPs, cytoskeleton stabilizers, and PI kinases contribute to guiding TLR9 signal transduction. However, some of the mechanisms behind TLR9 trafficking are still poorly understood.

Further studies are needed to fully understand the regulation of TLR9 and TLR4 signaling. An in-depth understanding of the regulatory mechanisms would allow, for example, steering the TLR9 pathway towards a specific immune response. Moreover, TAXI and trafficking regulators may become novel targets to prevent overt inflammation and potentiate vaccines and cancer therapies.

### Acknowledgments

IZ is supported by NIH grant 1R01AI121066-01A1, grant HHDCC P30 DK034854, the Harvard Medical School Milton Fund, CCFA Senior Research Awards, and the Cariplo Foundation. FG is supported by the Associazione Italiana per la Ricerca sul Cancro (IG 2016Id.18842), the Cariplo Foundation (Grant 2014-0655), and the Fondazione Regionale per la Ricerca Biomedica, FRRB.

### Abbreviations

ALRs	AIM2-like receptors
AP-1	activator protein 1

<b>BAD-LAMP</b>	brain and DC-associated LAMP-like molecule
<b>BLOC</b>	biogenesis of lysosome-related organelles complex
<b>BMDC</b>	bone marrow-derived dendritic cells
<b>BMDM</b>	bone marrow-derived macrophages
<b>CIA</b>	collagen-induced arthritis
<b>cDC</b>	conventional dendritic cells
<b>COPII</b>	coat-protein complex II
<b>CLRs</b>	C-type lectin receptors
<b>DAPI2</b>	DNAX-activating protein of 12 kDa
<b>DCs</b>	dendritic cells
<b>ER</b>	endoplasmic reticulum
<b>FHOD1</b>	forming-homology-domain-containing-protein 1
<b>GPI</b>	glycosylphosphatidylinositol
<b>HMGB</b>	high-mobility-group box
<b>HPS</b>	Hermansky-Pudlack syndrome
<b>HSV</b>	herpes simplex virus
<b>IKK</b>	I $\kappa$ B kinase
<b>IP3Rs</b>	inositol trisphosphate receptors
<b>IRAKs</b>	interleukin-1 receptor-associated kinases
<b>IRAP</b>	insulin-responsive aminopeptidase
<b>IRF</b>	interferon-regulatory factor
<b>ITAM</b>	immunoreceptor tyrosine-base activation motifs
<b>LAMPs</b>	lysosome-associated membrane proteins
<b>LPB</b>	LPS-binding protein
<b>LPS</b>	lipopolysaccharide
<b>LROs</b>	lysosome-related organelles
<b>MAPK</b>	mitogen-activated protein kinase
<b>MD-2</b>	myeloid-differentiation protein 2
<b>MS</b>	multiple sclerosis

<b>MyD88</b>	myeloid-differentiation primary response 88
<b>NFAT</b>	nuclear factor of activated T cells
<b>NF-<math>\kappa</math>B</b>	nuclear factor kappa-light-chain-enhancer of activated B cells
<b>NK</b>	natural killer
<b>NLRs</b>	NOD-like receptors
<b>OPN</b>	osteopontin
<b>PAMPs</b>	pathogen-associated molecular patterns
<b>PBMCs</b>	peripheral blood mononuclear cells
<b>pDCs</b>	plasmacytoid DCs
<b>PI3K</b>	phosphoinositol 3-OH kinase
<b>PIKfive</b>	phosphoinositide 3-phosphate 5-kinase
<b>PIs</b>	phosphoinositides
<b>PPRs</b>	pattern-recognition receptors
<b>PRAT4A</b>	protein associated with TLR4
<b>RA</b>	rheumatoid arthritis; RIG retinoic acid-inducible gene
<b>RIPK1</b>	receptor-interacting serine/threonine kinase 1
<b>RLRs</b>	RIG-I-like receptors
<b>Slc15a4</b>	solute-carrier protein superfamily member
<b>SLE</b>	systemic lupus erythematosus
<b>SS</b>	Sjögren's syndrome
<b>SSc</b>	systemic sclerosis
<b>Syk</b>	spleen tyrosine kinase
<b>TAB</b>	TAK-binding protein
<b>TAK</b>	TGF $\beta$ -activated kinase
<b>TANK</b>	TRAF family member-associated NF- $\kappa$ B activator
<b>TBK</b>	TANK-binding kinase-1
<b>TIR</b>	Toll/interleukin 1 receptor
<b>TIRAP</b>	TIR-containing adaptor protein
<b>TLRs</b>	Toll-like receptors

<b>TNF</b>	tumor necrosis factor
<b>TRADD</b>	TNF receptor-1-associated death-domain protein
<b>TRAF</b>	TNF receptor-associated factors
<b>TRAM</b>	TRIF-related adaptor molecule
<b>TRIF</b>	TIR-domain-containing adaptor inducing IFN- $\beta$
<b>TRPM7</b>	transient receptor potential cation channel subfamily M member 7
<b>UNC93B1</b>	unc-93 homolog B1
<b>UPEC</b>	uropathogenic <i>Escherichia Coli</i>
<b>VAMPs</b>	vesicle-associated membrane proteins

## References

1. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989); 54 Pt 1, 1–13.
2. Joffre O, Nolte MA, Sporri R, Reis e Sousa C Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev (2009); 227, 234–47. [PubMed: 19120488]
3. Fox RI and Kang HI Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am (1992); 18, 517–38. [PubMed: 1323135]
4. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006); 25, 417–28. [PubMed: 16973389]
5. Krishnamoorthy G, Saxena A, Mars LT, Domingues HS, Mentele R, Ben-Nun A, Lassmann H, Dormair K, Kurschus FC, Liblau RS, Wekerle H Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat Med (2009) 15, 626–32. [PubMed: 19483694]
6. Ntelis K, Solomou EE, Sakkas L, Lioussis SN, Daoussis D The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Semin Arthritis Rheum (2017); 47, 409–417. [PubMed: 28602360]
7. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004); 50, 380–6. [PubMed: 14872479]
8. Conrad C, Boyman O, Tonel G, Tun-Kyi A, Laggner U, de Fougères A, Kotlianski V, Gardner H, Nestle FO Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007); 13, 836–42. [PubMed: 17603494]
9. O'Neill LA, Golenbock D, Bowie AG The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. (2013); 13, 453–60. [PubMed: 23681101]
10. Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol (2003); 24, 528–33. [PubMed: 14552836]
11. O'Neill LA and Bowie AG The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007); 7, 353–64. [PubMed: 17457343]
12. Brubaker SW, Bonham KS, Zanoni I, Kagan JC Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol (2015); 33, 257–90. [PubMed: 25581309]
13. Akira S, Uematsu S, Takeuchi O Pathogen recognition and innate immunity. Cell (2006); 124, 783–801. [PubMed: 16497588]

14. Zhang SY, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, Segal D, Sancho-Shimizu V, Lorenzo L, Puel A, Picard C, Chappier A, Plancoulaine S, Titeux M, Cognet C, von Bernuth H, Ku CL, Casrouge A, Zhang XX, Barreiro L, Leonard J, Hamilton C, Lebon P, Heron B, Vallee L, Quintana-Murci L, Hovnanian A, Rozenberg F, Vivier E, Geissmann F, Tardieu M, Abel L, Casanova JL TLR3 deficiency in patients with herpes simplex encephalitis. *Science* (2007); 317, 1522–7. [PubMed: 17872438]
15. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Kariko K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. *Nature* (2008); 452, 591–7. [PubMed: 18368052]
16. Bernard JJ, Cowing-Zitron C, Nakatsuji T, Muehleisen B, Muto J, Borkowski AW, Martinez L, Greidinger EL, Yu BD, Gallo RL Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. *Nat Med* (2012); 18, 1286–90. [PubMed: 22772463]
17. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, Teti G, Beninati C Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. *Nat Immunol* (2009); 10, 587–94. [PubMed: 19430477]
18. Guiducci C, Gong M, Cepika AM, Xu Z, Tripodo C, Bennett L, Crain C, Quartier P, Cush JJ, Pascual V, Coffman RL, Barrat FJ RNA recognition by human TLR8 can lead to autoimmune inflammation. *J Exp Med* (2013); 210, 2903–19. [PubMed: 24277153]
19. Forsbach A, Nemorin JG, Montino C, Muller C, Samulowitz U, Vicari AP, Jurk M, Mutwiri GK, Krieg AM, Lipford GB, Vollmer J Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. *J Immunol* (2008); 180, 3729–38. [PubMed: 18322178]
20. Coban C, Igari Y, Yagi M, Reimer T, Koyama S, Aoshi T, Ohata K, Tsukui T, Takeshita F, Sakurai K, Ikegami T, Nakagawa A, Horii T, Nunez G, Ishii KJ, Akira S Immunogenicity of whole-parasite vaccines against *Plasmodium falciparum* involves malarial hemozoin and host TLR9. *Cell Host Microbe* (2010); 7, 50–61. [PubMed: 20114028]
21. Parroche P, Lauw FN, Goutagny N, Latz E, Monks BG, Visintin A, Halmen KA, Lamphier M, Olivier M, Bartholomeu DC, Gazzinelli RT, Golenbock DT Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. *Proc Natl Acad Sci U S A* (2007); 104, 1919–24. [PubMed: 17261807]
22. Li XD and Chen ZJ Sequence specific detection of bacterial 23S ribosomal RNA by TLR13. *Elife* 1, e00102. [PubMed: 23110254]
23. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, Yang J, Fu S, Zhang D (2011) A novel Toll-like receptor that recognizes vesicular stomatitis virus. *J Biol Chem* (2012); 286, 4517–24. [PubMed: 21131352]
24. Mathur R, Oh H, Zhang D, Park SG, Seo J, Koblansky A, Hayden MS, Ghosh S A mouse model of *Salmonella typhi* infection. *Cell* (2012); 151, 590–602. [PubMed: 23101627]
25. Yarovinsky F, Zhang D, Andersen JF, Bannenberg GL, Serhan CN, Hayden MS, Hieny S, Sutterwala FS, Flavell RA, Ghosh S, Sher A TLR11 activation of dendritic cells by a protozoan profilin-like protein. *Science* (2005); 308, 1626–9. [PubMed: 15860593]
26. Koblansky AA, Jankovic D, Oh H, Hieny S, Sungnak W, Mathur R, Hayden MS, Akira S, Sher A, Ghosh S Recognition of profilin by Toll-like receptor 12 is critical for host resistance to *Toxoplasma gondii*. *Immunity* (2013); 38, 119–30. [PubMed: 23246311]
27. Yamamoto M, Sato S, Hemmi H, Uematsu S, Hoshino K, Kaisho T, Takeuchi O, Takeda K, Akira S TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. *Nat Immunol* (2003); 4, 1144–50. [PubMed: 14556004]
28. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* (2005); 434, 772–7. [PubMed: 15800576]
29. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. *Nature* (2005); 434, 1035–40. [PubMed: 15815647]

30. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. *Nature* (2008); 452, 234–8. [PubMed: 18305481]
31. Lee BL, Moon JE, Shu JH, Yuan L, Newman ZR, Schekman R, Barton GM UNC93B1 mediates differential trafficking of endosomal TLRs. *Elife* (2013); 2, e00291. [PubMed: 23426999]
32. Pelka K, Bertheloot D, Reimer E, Phulphagar K, Schmidt SV, Christ A, Stahl R, Watson N, Miyake K, Hacoheh N, Haas A, Brinkmann MM, Marshak-Rothstein A, Meissner F, Latz E The Chaperone UNC93B1 Regulates Toll-like Receptor Stability Independently of Endosomal TLR Transport. *Immunity* (2018); 48, 911–922.e7. [PubMed: 29768176]
33. Yang Y, Liu B, Dai J, Srivastava PK, Zammit DJ, Lefrancois L, Li Z Heat shock protein gp96 is a master chaperone for toll-like receptors and is important in the innate function of macrophages. *Immunity* (2007); 26, 215–26. [PubMed: 17275357]
34. Takahashi K, Shibata T, Akashi-Takamura S, Kiyokawa T, Wakabayashi Y, Tanimura N, Kobayashi T, Matsumoto F, Fukui R, Kouro T, Nagai Y, Takatsu K, Saitoh S, Miyake K A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses. *J Exp Med* (2007); 204, 2963–76. [PubMed: 17998391]
35. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the *Drosophila* Toll protein signals activation of adaptive immunity. *Nature* (1997); 388, 394–7. [PubMed: 9237759]
36. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. *Nat Immunol* (2008); 9, 361–8. [PubMed: 18297073]
37. Brandt KJ, Fickentscher C, Kruithof EK, de Moerloose P TLR2 ligands induce NF-kappaB activation from endosomal compartments of human monocytes. *PLoS One* (2013); 8, e80743. [PubMed: 24349012]
38. Barbalat R, Lau L, Locksley RM, Barton GM Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. *Nat Immunol* (2009); 10, 1200–7. [PubMed: 19801985]
39. Steimle A, Autenrieth IB, Frick JS Structure and function: Lipid A modifications in commensals and pathogens. *Int J Med Microbiol* (2016); 306, 290–301. [PubMed: 27009633]
40. Rittig MG, Kaufmann A, Robins A, Shaw B, Sprenger H, Gemsa D, Foulongne V, Rouot B, Dornand J Smooth and rough lipopolysaccharide phenotypes of *Brucella* induce different intracellular trafficking and cytokine/chemokine release in human monocytes. *J Leukoc Biol* (2003); 74, 1045–55. [PubMed: 12960272]
41. Mathison JC, Tobias PS, Wolfson E, Ulevitch RJ Plasma lipopolysaccharide (LPS)-binding protein. A key component in macrophage recognition of gram-negative LPS. *J Immunol* (1992); 149, 200–6. [PubMed: 1607653]
42. Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Kimoto M Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. *Int Immunol* (2010); 22, 271–80. [PubMed: 20133493]
43. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. *J Biol Chem* (2001); 276, 21129–35. [PubMed: 11274165]
44. Schmitz G and Orso E CD14 signalling in lipid rafts: new ligands and co-receptors. *Curr Opin Lipidol* (2002); 13, 513–21. [PubMed: 12352015]
45. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *Nature* (2009); 458, 1191–5. [PubMed: 19252480]
46. Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, Weiss JP Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. *Proc Natl Acad Sci U S A* (2004); 101, 4186–91. [PubMed: 15010525]
47. Zanoni I, Ostuni R, Capuano G, Collini M, Caccia M, Ronchi AE, Rocchetti M, Mingozzi F, Foti M, Chirico G, Costa B, Zaza A, Ricciardi-Castagnoli P, Granucci F CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. *Nature* (2009); 460, 264–8. [PubMed: 19525933]



48. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. *Science* (2013); 341, 1250–3. [PubMed: 24031018]
49. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, Miyake K, Zhang J, Lee WP, Muszynski A, Forsberg LS, Carlson RW, Dixit VM Noncanonical inflammasome activation by intracellular LPS independent of TLR4. *Science* (2013); 341, 1246–9. [PubMed: 23887873]
50. Broz P and Dixit VM Inflammasomes: mechanism of assembly, regulation and signalling. *Nat Rev Immunol* (2016); 16, 407–20. [PubMed: 27291964]
51. Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, Hu L, Shao F Inflammatory caspases are innate immune receptors for intracellular LPS. *Nature* (2014); 514, 187–92. [PubMed: 25119034]
52. Medzhitov R Toll-like receptors and innate immunity. *Nat Rev Immunol* (2001); 1, 135–45. [PubMed: 11905821]
53. Motshwene PG, Moncrieffe MC, Grossmann JG, Kao C, Ayaluru M, Sandercock AM, Robinson CV, Latz E, Gay NJ An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. *J Biol Chem* (2009); 284, 25404–11. [PubMed: 19592493]
54. Piao W, Ru LW, Piepenbrink KH, Sundberg EJ, Vogel SN, Toshchakov VY Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain. *Proc Natl Acad Sci U S A* (2013); 110, 19036–41. [PubMed: 24194546]
55. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. *Nat Immunol* (2003); 4, 491–6. [PubMed: 12692549]
56. Zanoni I, Ostuni R, Marek LR, Barresi S, Barbalat R, Barton GM, Granucci F, Kagan JC CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. *Cell* (2011); 147, 868–80. [PubMed: 22078883]
57. West MA, Wallin RP, Matthews SP, Svensson HG, Zaru R, Ljunggren HG, Prescott AR, Watts C Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. *Science* (2004); 305, 1153–7. [PubMed: 15326355]
58. Thomas L, Bielemeier A, Lambert PA, Darveau RP, Marshall LJ, Devitt A The N-terminus of CD14 acts to bind apoptotic cells and confers rapid-tethering capabilities on non-myeloid cells. *PLoS One* (2013); 8, e70691. [PubMed: 23936239]
59. Zanoni I, Spreafico R, Bodio C, Di Gioia M, Cigni C, Broggi A, Gorletta T, Caccia M, Chirico G, Sironi L, Collini M, Colombo MP, Garbi N, Granucci F IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. *Cell Rep* (2013); 4, 1235–49. [PubMed: 24055061]
60. Jiang Z, Georgel P, Du X, Shamel L, Sovath S, Mudd S, Huber M, Kalis C, Keck S, Galanos C, Freudenberg M, Beutler B CD14 is required for MyD88-independent LPS signaling. *Nat Immunol* (2005); 6, 565–70. [PubMed: 15895089]
61. Chiang CY, Veckman V, Limmer K, David M Phospholipase Cgamma-2 and intracellular calcium are required for lipopolysaccharide-induced Toll-like receptor 4 (TLR4) endocytosis and interferon regulatory factor 3 (IRF3) activation. *J Biol Chem* (2012); 287, 3704–9. [PubMed: 22158869]
62. Schappe MS, Sztajn K, Stremaska ME, Mendu SK, Downs TK, Seegren PV, Mahoney MA, Dixit S, Krupa JK, Stipes EJ, Rogers JS, Adamson SE, Leitinger N, Desai BN Chanzyme TRPM7 Mediates the Ca(2+) Influx Essential for Lipopolysaccharide-Induced Toll-Like Receptor 4 Endocytosis and Macrophage Activation. *Immunity* (2018); 48, 59–74.e5. [PubMed: 29343440]
63. Granucci F The Family of LPS Signal Transducers Increases: the Arrival of Chanzymes. *Immunity* (2018); 48, 4–6. [PubMed: 29343439]
64. Tan Y, Zanoni I, Cullen TW, Goodman AL, Kagan JC Mechanisms of Toll-like Receptor 4 Endocytosis Reveal a Common Immune-Evasion Strategy Used by Pathogenic and Commensal Bacteria. *Immunity* (2015); 43, 909–22. [PubMed: 26546281]
65. Ling GS, Bennett J, Woollard KJ, Szajna M, Fossati-Jimack L, Taylor PR, Scott D, Franzoso G, Cook HT, Botto M Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages. *Nat Commun* (2014); 5, 3039. [PubMed: 24423728]

66. Ghosh M, Subramani J, Rahman MM, Shapiro LH CD13 restricts TLR4 endocytic signal transduction in inflammation. *J Immunol* (2015); 194, 4466–76. [PubMed: 25801433]
67. Perkins DJ, Richard K, Hansen AM, Lai W, Nallar S, Koller B, Vogel SN Autocrine-paracrine prostaglandin E2 signaling restricts TLR4 internalization and TRIF signaling. *Nat Immunol* (2018); 19, 1309–1318. [PubMed: 30397349]
68. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT TLR9 signals after translocating from the ER to CpG DNA in the lysosome. *Nat Immunol* (2004); 5, 190–8. [PubMed: 14716310]
69. Barton GM, Kagan JC, Medzhitov R Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. *Nat Immunol* (2006);7, 49–56. [PubMed: 16341217]
70. Sasai M, Linehan MM, Iwasaki A Bifurcation of Toll-like receptor 9 signaling by adaptor protein 3. *Science* (2010); 329, 1530–4. [PubMed: 20847273]
71. Babdor J, Descamps D, Adiko AC, Tohme M, Maschalidi S, Evnouchidou I, Vasconcellos LR, De Luca M, Mauvais FX, Garfa-Traore M, Brinkmann MM, Chignard M, Manoury B, Saveanu L IRAP(+) endosomes restrict TLR9 activation and signaling. *Nat Immunol* (2017); 18, 509–518. [PubMed: 28319098]
72. Combes A, Camosseto V, N'Guessan P, Arguello RJ, Mussard J, Caux C, Bendriss-Vermare N, Pierre P, Gatti E BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. *Nat Commun* (2017); 8, 913. [PubMed: 29030552]
73. Webster B, Werneke SW, Zafirova B, This S, Coleon S, Decembre E, Paidassi H, Bouvier I, Joubert PE, Duffy D, Walzer T, Albert ML, Dreux M Plasmacytoid dendritic cells control dengue and Chikungunya virus infections via IRF7-regulated interferon responses. *Elife* (2018); 7.
74. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. *Immunity* (2010); 33, 955–66. [PubMed: 21130004]
75. Saveanu L, Carroll O, Weimershaus M, Guermonprez P, Firat E, Lindo V, Greer F, Davoust J, Kratzer R, Keller SR, Niedermann G, van Endert P IRAP identifies an endosomal compartment required for MHC class I cross-presentation. *Science* (2009); 325, 213–7. [PubMed: 19498108]
76. Weimershaus M, Maschalidi S, Sepulveda F, Manoury B, van Endert P, Saveanu L Conventional dendritic cells require IRAP-Rab14 endosomes for efficient cross-presentation. *J Immunol* (2012); 188, 1840–6. [PubMed: 22238454]
77. Weimershaus M, Mauvais FX, Saveanu L, Adiko C, Babdor J, Abramova A, Montealegre S, Lawand M, Evnouchidou I, Huber KJ, Chadt A, Zwick M, Vargas P, Dussiot M, Lennon-Dumenil AM, Brocker T, Al-Hasani H, van Endert P Innate Immune Signals Induce Anterograde Endosome Transport Promoting MHC Class I Cross-Presentation. *Cell Rep* (2018); 24, 3568–3581. [PubMed: 30257216]
78. Blasius AL, Arnold CN, Georgel P, Rutschmann S, Xia Y, Lin P, Ross C, Li X, Smart NG, Beutler B Slc15a4, AP-3, and Hermansky-Pudlak syndrome proteins are required for Toll-like receptor signaling in plasmacytoid dendritic cells. *Proc Natl Acad Sci U S A* (2010); 107, 19973–8. [PubMed: 21045126]
79. Bultema JJ, Ambrosio AL, Burek CL, Di Pietro SM BLOC-2, AP-3, and AP-1 proteins function in concert with Rab38 and Rab32 proteins to mediate protein trafficking to lysosome-related organelles. *J Biol Chem* (2012); 287, 19550–63. [PubMed: 22511774]
80. Feng L, Seymour AB, Jiang S, To A, Peden AA, Novak EK, Zhen L, Rusiniak ME, Eicher EM, Robinson MS, Gorin MB, Swank RT The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. *Hum Mol Genet* (1999); 8, 323–30. [PubMed: 9931340]
81. Prandini A, Salvi V, Colombo F, Moratto D, Lorenzi L, Vermi W, De Francesco MA, Notarangelo LD, Porta F, Plebani A, Facchetti F, Sozzani S, Badolato R Impairment of dendritic cell functions in patients with adaptor protein-3 complex deficiency. *Blood* (2016); 127, 3382–6. [PubMed: 27207797]
82. De Matteis MA and Godi A PI-loting membrane traffic. *Nat Cell Biol* (2004); 6, 487–92. [PubMed: 15170460]

83. Kutateladze TG Translation of the phosphoinositide code by PI effectors. *Nat Chem Biol* (2010); 6, 507–13. [PubMed: 20559318]
84. Kagan JC and Medzhitov R Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. *Cell* (2006); 125, 943–55. [PubMed: 16751103]
85. Catimel B, Schieber C, Condrón M, Patsiouras H, Connolly L, Catimel J, Nice EC, Burgess AW, Holmes AB The PI(3,5)P2 and PI(4,5)P2 interactomes. *J Proteome Res* (2008); 7, 5295–313. [PubMed: 19367725]
86. Shisheva A PIKfyve: Partners, significance, debates and paradoxes. *Cell Biol Int* (2008); 32, 591–604. [PubMed: 18304842]
87. Hazeki K, Uehara M, Nigorikawa K, Hazeki O PIKfyve regulates the endosomal localization of CpG oligodeoxynucleotides to elicit TLR9-dependent cellular responses. *PLoS One* (2013); 8, e73894. [PubMed: 24040108]
88. Hayashi K, Sasai M, Iwasaki A Toll-like receptor 9 trafficking and signaling for type I interferons requires PIKfyve activity. *Int Immunol* (2015); 27, 435–45. [PubMed: 25925170]
89. Moresco EM and Beutler B Special delivery: granulins brings CpG DNA to Toll-like receptor 9. *Immunity* (2011); 34, 453–5. [PubMed: 21511177]
90. Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM, Nishihara M, Ploegh HL Granulin is a soluble cofactor for toll-like receptor 9 signaling. *Immunity* (2011); 34, 505–13. [PubMed: 21497117]
91. Bateman A, Belcourt D, Bennett H, Lazure C, Solomon S Granulins, a novel class of peptide from leukocytes. *Biochem Biophys Res Commun* (1990); 173, 1161–8. [PubMed: 2268320]
92. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. *Cell* (2002); 111, 867–78. [PubMed: 12526812]
93. Plowman GD, Green JM, Neubauer MG, Buckley SD, McDonald VL, Todaro GJ, Shoyab M The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth. *J Biol Chem* (1992); 267, 13073–8. [PubMed: 1618805]
94. Shoyab M, McDonald VL, Byles C, Todaro GJ, Plowman GD Epithelins 1 and 2: isolation and characterization of two cysteine-rich growth-modulating proteins. *Proc Natl Acad Sci U S A* (1990); 87, 7912–6. [PubMed: 2236009]
95. Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, Ohta S, Inoue Y, Arinobu Y, Niino H, Horiuchi T, Akashi K Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. *Arthritis Res Ther* (2012); 14, R244. [PubMed: 23140401]
96. Chen X, Wen Z, Xu W, Xiong S Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization. *PLoS One* (2013); 8, e65542. [PubMed: 23755248]
97. Qiao B, Wu J, Chu YW, Wang Y, Wang DP, Wu HS, Xiong SD Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. *Rheumatology (Oxford)* (2005); 44, 1108–14. [PubMed: 15840592]
98. Wu J, Su W, Powner MB, Liu J, Copland DA, Fruttiger M, Madeddu P, Dick AD, Liu L Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways. *Sci Rep* (2016); 6, 31873. [PubMed: 27558877]
99. Nightingale K, Dimitrov S, Reeves R, Wolffe AP Evidence for a shared structural role for HMG1 and linker histones B4 and H1 in organizing chromatin. *Embo j* (1996); 15, 548–61. [PubMed: 8599938]
100. Agresti A, Scaffidi P, Riva A, Caiolfa VR, Bianchi ME GR and HMGB1 interact only within chromatin and influence each other's residence time. *Mol Cell* (2005); 18, 109–21. [PubMed: 15808513]
101. Lange SS, Mitchell DL, Vasquez KM High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. *Proc Natl Acad Sci U S A* (2008); 105, 10320–5. [PubMed: 18650382]
102. van Gent DC, Hiom K, Paull TT, Gellert M Stimulation of V(D)J cleavage by high mobility group proteins. *Embo j* (1997); 16, 2665–70. [PubMed: 9184213]

103. Little AJ, Corbett E, Ortega F, Schatz DG Cooperative recruitment of HMGB1 during V(D)J recombination through interactions with RAG1 and DNA. *Nucleic Acids Res* (2013); 41, 3289–301. [PubMed: 23325855]
104. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. *Mol Cell Biol* (1998); 18, 4471–87. [PubMed: 9671457]
105. Scaffidi P, Misteli T, Bianchi ME Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. *Nature* (2002); 418, 191–5. [PubMed: 12110890]
106. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H Role of HMGB1 in apoptosis-mediated sepsis lethality. *J Exp Med* (2006); 203, 1637–42. [PubMed: 16818669]
107. Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol* (2007); 8, 487–96. [PubMed: 17417641]
108. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, Bianchi ME, Wang H, Chu WM A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. *Blood* (2007); 110, 1970–81. [PubMed: 17548579]
109. Ewald SE, Lee BL, Lau L, Wickcliffe KE, Shi GP, Chapman HA, Barton GM (2008) The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. *Nature* 456, 658–62. [PubMed: 18820679]
110. Park B, Brinkmann MM, Spooner E, Lee CC, Kim YM, Ploegh HL Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. *Nat Immunol* (2008); 9, 1407–14. [PubMed: 18931679]
111. Seya T, Shingai M, Matsumoto M [Toll-like receptors that sense viral infection]. *Uirusu* (2004); 54, 1–8. [PubMed: 15449898]
112. Sepulveda FE, Maschalidi S, Colisson R, Heslop L, Ghirelli C, Sakka E, Lennon-Dumenil AM, Amigorena S, Cabanie L, Manoury B Critical role for asparagine endopeptidase in endocytic Toll-like receptor signaling in dendritic cells. *Immunity* (2009) 31, 737–48. [PubMed: 19879164]
113. Ewald SE, Engel A, Lee J, Wang M, Bogyo M, Barton GM Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase. *J Exp Med* (2011); 208, 643–51. [PubMed: 21402738]
114. Chockalingam A, Cameron JL, Brooks JC, Leifer CA Negative regulation of signaling by a soluble form of toll-like receptor 9. *Eur J Immunol* (2011); 41, 2176–84. [PubMed: 21604257]
115. Lee S, Kang D, Ra EA, Lee TA, Ploegh HL, Park B Negative self-regulation of TLR9 signaling by its N-terminal proteolytic cleavage product. *J Immunol* (2014); 193, 3726–35. [PubMed: 25187653]
116. Onji M, Kanno A, Saitoh S, Fukui R, Motoi Y, Shibata T, Matsumoto F, Lamichhane A, Sato S, Kiyono H, Yamamoto K, Miyake K An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. *Nat Commun* (2013); 4, 1949. [PubMed: 23752491]
117. Sinha SS, Cameron J, Brooks JC, Leifer CA Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events. *J Immunol* (2016); 197, 1343–52. [PubMed: 27421483]
118. Aksoy E, Taboubi S, Torres D, Delbauve S, Hachani A, Whitehead MA, Pearce WP, Berenjeno IM, Nock G, Filloux A, Beyaert R, Flamand V, Vanhaesebroeck B The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. *Nat Immunol* (2012); 13, 1045–1054. [PubMed: 23023391]
119. Bonham KS, Orzalli MH, Hayashi K, Wolf AI, Glanemann C, Weninger W, Iwasaki A, Knipe DM, Kagan JC A promiscuous lipid-binding protein diversifies the subcellular sites of toll-like receptor signal transduction. *Cell* (2014); 156, 705–16. [PubMed: 24529375]
120. Sato A, Linehan MM, Iwasaki A Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. *Proc Natl Acad Sci U S A* (2006); 103, 17343–8. [PubMed: 17085599]

121. Piao W, Shirey KA, Ru LW, Lai W, Szmazinski H, Snyder GA, Sundberg EJ, Lakowicz JR, Vogel SN, Toshchakov VY A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of Influenza. *Cell Rep* (2015); 11, 1941–52. [PubMed: 26095366]
122. Kavran JM, Klein DE, Lee A, Falasca M, Isakoff SJ, Skolnik EY, Lemmon MA Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. *J Biol Chem* (1998); 273, 30497–508. [PubMed: 9804818]
123. Ve T, Vajjhala PR, Hedger A, Croll T, DiMaio F, Horsefield S, Yu X, Lavrencic P, Hassan Z, Morgan GP, Mansell A, Mobli M, O'Carroll A, Chauvin B, Gambin Y, Sierecki E, Landsberg MJ, Stacey KJ, Egelman EH, Kobe B Structural basis of TIR-domain-assembly formation in MAL- and MyD88-dependent TLR4 signaling. *Nat Struct Mol Biol* (2017); 24, 743–751. [PubMed: 28759049]
124. Javmen A, Szmazinski H, Lakowicz JR, Toshchakov VY Blocking TIR Domain Interactions in TLR9 Signaling. *J Immunol* (2018); 201, 995–1006. [PubMed: 29914886]
125. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, Espevik T, Golenbock DT Ligand-induced conformational changes allosterically activate Toll-like receptor 9. *Nat Immunol* (2007); 8, 772–9. [PubMed: 17572678]
126. Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S, Penninger JM, Wesche H, Ohashi PS, Mak TW, Yeh WC Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. *Nature* (2002); 416, 750–6. [PubMed: 11923871]
127. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O, Akira S Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. *Nat Immunol* (2008); 9, 684–91. [PubMed: 18438411]
128. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. *J Exp Med* (2000); 192, 595–600. [PubMed: 10952730]
129. Siggs OM, Berger M, Krebs P, Arnold CN, Eidenschenk C, Huber C, Pirie E, Smart NG, Khovananth K, Xia Y, McInerney G, Karlsson Hedestam GB, Nemazee D, Beutler B A mutation of Ikbkg causes immune deficiency without impairing degradation of IkappaB alpha. *Proc Natl Acad Sci U S A* (2010); 107, 3046–51. [PubMed: 20133626]
130. Min Y, Kim MJ, Lee S, Chun E, Lee KY Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFkB activation and autophagy activation. *Autophagy* (2018); 14, 1347–1358. [PubMed: 29929436]
131. Scheidereit C IkappaB kinase complexes: gateways to NF-kappaB activation and transcription. *Oncogene* (2006); 25, 6685–705. [PubMed: 17072322]
132. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB TAK1 is critical for IkappaB kinase-mediated activation of the NF-kappaB pathway. *J Mol Biol* (2003); 326, 105–15. [PubMed: 12547194]
133. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, Jegga AG, Aronow BJ, Ghosh G, Rickert RC, Karin M Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. *Embo j* (2004); 23, 4202–10. [PubMed: 15470505]
134. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. *Cell* (2000); 103, 351–61. [PubMed: 11057907]
135. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ TAK1 is a ubiquitin-dependent kinase of MKK and IKK. *Nature* (2001); 412, 346–51. [PubMed: 11460167]
136. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. *Nature* (1999); 398, 252–6. [PubMed: 10094049]
137. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T, Honda K Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. *Proc Natl Acad Sci U S A* (2006); 103, 15136–41. [PubMed: 17018642]




138. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, Taniguchi T Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. *Nature* (2005); 434, 243–9. [PubMed: 15665823]
139. Hoshino K, Sasaki I, Sugiyama T, Yano T, Yamazaki C, Yasui T, Kikutani H, Kaisho T Critical role of IkappaB Kinase alpha in TLR7/9-induced type I IFN production by conventional dendritic cells. *J Immunol* (2010); 184, 3341–5. [PubMed: 20200270]
140. Schmitz F, Heit A, Guggemoos S, Krug A, Mages J, Schiemann M, Adler H, Drexler I, Haas T, Lang R, Wagner H Interferon-regulatory-factor 1 controls Toll-like receptor 9-mediated IFN-beta production in myeloid dendritic cells. *Eur J Immunol* (2007); 37, 315–27. [PubMed: 17273999]
141. Yang K, Puel A, Zhang S, Eidenschenk C, Ku CL, Casrouge A, Picard C, von Bernuth H, Senechal B, Plancoulaine S, Al-Hajjar S, Al-Ghonaium A, Marodi L, Davidson D, Speert D, Roifman C, Garty BZ, Ozinsky A, Barrat FJ, Coffman RL, Miller RL, Li X, Lebon P, Rodriguez-Gallego C, Chapel H, Geissmann F, Jouanguy E, Casanova JL Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda is IRAK-4 dependent and redundant for protective immunity to viruses. *Immunity* (2005); 23, 465–78. [PubMed: 16286015]
142. Honda K, Yanai H, Mizutani T, Negishi H, Shimada N, Suzuki N, Ohba Y, Takaoka A, Yeh WC, Taniguchi T Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. *Proc Natl Acad Sci U S A* (2004); 101, 15416–21. [PubMed: 15492225]
143. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. *Nature* (2006); 439, 204–7. [PubMed: 16306937]
144. Oganessian G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, Perry A, Cheng G (2006) Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. *Nature* 439, 208–11. [PubMed: 16306936]
145. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, Matsuda M, Coban C, Ishii KJ, Kawai T, Takeuchi O, Akira S Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon- $\alpha$  induction. *J Exp Med* (2005); 201, 915–23. [PubMed: 15767370]
146. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, Terai K, Matsuda M, Inoue J, Uematsu S, Takeuchi O, Akira S Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. *Nat Immunol* (2004); 5, 1061–8. [PubMed: 15361868]
147. Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, Akira S, Kaisho T IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. *Nature* (2006); 440, 949–53. [PubMed: 16612387]
148. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, Cantor H Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. *Nat Immunol* (2006); 7, 498–506. [PubMed: 16604075]
149. Cao W, Manicassamy S, Tang H, Kasturi SP, Pirani A, Murthy N, Pulendran B Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. *Nat Immunol* (2008); 9, 1157–64. [PubMed: 18758466]
150. Lou H and Pickering MC Extracellular DNA and autoimmune diseases. *Cell Mol Immunol* (2018); 15, 746–755. [PubMed: 29553134]
151. Dieker J, Hilbrands L, Thielen A, Dijkman H, Berden JH, van der Vlag J Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. *Arthritis Res Ther* (2015); 17, 103. [PubMed: 25886192]
152. Yasuda K, Richez C, Uccellini MB, Richards RJ, Bonegio RG, Akira S, Monestier M, Corley RB, Viglianti GA, Marshak-Rothstein A, Rifkin IR Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. *J Immunol* (2009); 183, 3109–17. [PubMed: 19648272]
153. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi




- H Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. *Science* (2008); 319, 624–7. [PubMed: 18239127]
154. Papadimitraki ED, Choulaki C, Koutala E, Bertsiaris G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. *Arthritis Rheum* (2006); 54, 3601–11. [PubMed: 17075805]
  155. Jin O, Kavikondala S, Sun L, Fu R, Mok MY, Chan A, Yeung J, Lau CS Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression. *Lupus* (2008); 17, 654–62. [PubMed: 18625638]
  156. Mortezaigholi S, Babaloo Z, Rahimzadeh P, Namdari H, Ghaedi M, Gharibdoost F, Mirzaei R, Bidad K, Salehi E Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation on IFN-alpha production in SLE patients. *Immunopharmacol Immunotoxicol* (2017); 39, 11–18. [PubMed: 28049380]
  157. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. *J Exp Med* (2005) 202, 321–31. [PubMed: 16027240]
  158. Nickerson KM, Christensen SR, Shupe J, Kashgarian M, Kim D, Elkon K, Shlomchik MJ TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus. *J Immunol* (2010); 184, 1840–8. [PubMed: 20089701]
  159. Santiago-Raber ML, Dunand-Sauthier I, Wu T, Li QZ, Uematsu S, Akira S, Reith W, Mohan C, Kotzin BL, Izui S Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice. *J Autoimmun* (2010); 34, 339–48. [PubMed: 19944565]
  160. Fukui R, Saitoh S, Kanno A, Onji M, Shibata T, Ito A, Matsumoto M, Akira S, Yoshida N, Miyake K Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. *Immunity* (2011); 35, 69–81. [PubMed: 21683627]
  161. Hoffmann MH, Skriner K, Herman S, Baumann C, Steiner CW, Ospelt C, Meyer B, Gleiss A, Pfatschbacher J, Niederreiter B, Tuncel J, Zanoni G, Steiner G Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. *J Autoimmun* (2011); 36, 288–300. [PubMed: 21439786]
  162. Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, Gray M A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. *Proc Natl Acad Sci U S A* (2012); 109, 887–92. [PubMed: 22207622]
  163. Paulsen F, Pufe T, Conradi L, Varoga D, Tsokos M, Papendieck J, Petersen W Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes. *J Pathol* (2002); 198, 369–77. [PubMed: 12375270]
  164. Lai Y and Gallo RL AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. *Trends Immunol* (2009); 30, 131–41. [PubMed: 19217824]
  165. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, Mellman I, Schroder JM, Liu YJ, Gilliet M Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. *Nature* (2007); 449, 564–9. [PubMed: 17873860]
  166. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ, Gilliet M Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med* (2005); 202, 135–43. [PubMed: 15998792]
  167. Lebre MC, van der Aar AM, van Baarsen L, van Capel TM, Schuitemaker JH, Kapsenberg ML, de Jong EC Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. *J Invest Dermatol* (2007); 127, 331–41. [PubMed: 17068485]
  168. Morizane S, Yamasaki K, Mühleisen B, Kotol PF, Murakami M, Aoyama Y, Iwatsuki K, Hata T, Gallo RL Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. *J Invest Dermatol* (2012); 132, 135–43. [PubMed: 21850017]
  169. McAlpine W, Sun L, Wang KW, Liu A, Jain R, San Miguel M, Wang J, Zhang Z, Hayse B, McAlpine SG, Choi JH, Zhong X, Ludwig S, Russell J, Zhan X, Choi M, Li X, Tang M, Moresco EMY, Beutler B, Turer E Excessive endosomal TLR signaling causes inflammatory disease in

- mice with defective SMCR8-WDR41-C9ORF72 complex function. *Proc Natl Acad Sci U S A* (2018); 115(49):E11523–E11531 [PubMed: 30442666]
170. Zhang Y, Burberry A, Wang JY, Sandoe J, Ghosh S, Udeshi ND, Svinkina T, Mordes DA, Mok J, Charlton M, Li QZ, Carr SA, Eggan K The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis. *Genes Dev* (2018); 32, 929–943. [PubMed: 29950492]
171. Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V, Halloran MA, Gleeson PA, Blair IP, Soo KY, King AE, Atkin JD C9ORF72, implicated in amyotrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. *Hum Mol Genet* (2014); 23, 3579–95. [PubMed: 24549040]
172. Rosadini CV and Kagan JC Early innate immune responses to bacterial LPS. *Curr Opin Immunol* (2017); 44, 14–19. [PubMed: 27842237]



**Figure 1. TLR4 plasma membrane and endosome signaling**

A) LPB protein extracts LPS from the bacterial cell wall and transfers it to CD14. In the presence of LPS, CD14 allows the translocation of the TLR4-MD-2 complex to lipid rafts, where it dimerizes. Then the formation of the ‘myddosome’ complex (containing TIRAP, MyD88, and IRAKs) occurs. IRAKs recruit TRAF6, which interacts with TAB1/2/3 and TAK1 for the activation of NF- $\kappa$ B and AP-1. Thus, CD14 binds directly to LPS and induces a signal that leads to the activation of NFAT transcription factors. B) The LPS receptor complex is internalized through a CD14-dependent mechanism, involving ITAM-bearing molecules, Syk tyrosine kinase, and PLC $\gamma$ 2. Calcium mobilization from the extracellular space via TRPM7 is also required, at least in part. In the endosome, TRAM-TRIF adaptor molecules bind to TRAF3, which interacts with TANK to recruit IKKs and TBK1, which activate IRF3.



### Figure 2. TLR9 intracellular trafficking and pathway

At steady state, TLR9 co-localizes to the ER with UNC93B1 (1). TLR9 follows the secretory pathway through the Golgi (2) to reach the plasma membrane (3) via COPII+ vesicles. TLR9 is endocytosed in a clathrin-dependent manner via AP-2 to enter the endolysosomal system, where acidification of the endosomes allows proteolytic cleavage of TLR9 by cathepsins and endopeptidases (4). In parallel, the TLR9 ligand, CpG, is endocytosed in a clathrin-dependent manner (5) and meets its cognate receptor (6). Here, the pathway bifurcates. IRAP<sup>+</sup> early endosomes carry both TLR9 and CpG, and the presence of this aminopeptidase results in reduced immune activation, as IRAP interacts with actin-nucleation factors to slow TLR9 trafficking to the late endosomes. In human pDCs, BAD-LAMP facilitates the trafficking of TLR9 and CpG.